Gilead Sciences is buying the cancer treatment company Forty Seven in a deal valued at approximately $4.9 billion. Gilead, based in Foster City, California, will pay $95.50 for each Forty Seven Inc.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

-- Presented Updated Data for Magrolimab Showing Robust, Durable Activity in MDS and AML ---- Presented Foundational Preclinical Data for FSI-174 and Entered into Collaborations with bluebird bio and ...

MENLO PARK, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, ...

Forty Seven surges on confirmation that it and its flagship cancer-fighting treatment are being bought by Gilead Sciences for $95.50 a share in cash.

Explore the Forty Seven stock price history with detailed daily historical prices, including open, high, low, close, and volume data. Review past trends, identify key price levels, and find the ...

(Reuters) - Gilead Sciences Inc said on Monday it would buy Forty Seven Inc for $4.9 billion in cash, adding an experimental treatment that targets blood cancer to its portfolio of oncology drugs.

– Gilead Gains Forty Seven’s Investigational Immuno-Oncology Therapy in Multiple Clinical Studies for Diseases Including Myelodysplastic Syndrome, Acute Myeloid Leukemia and Diffuse Large B-Cell ...